Histogenics (HSGX) Upgraded at ValuEngine

ValuEngine upgraded shares of Histogenics (NASDAQ:HSGX) from a strong sell rating to a sell rating in a research note issued to investors on Friday morning.

Several other equities research analysts have also commented on HSGX. Zacks Investment Research lowered Histogenics from a buy rating to a hold rating in a research note on Monday, October 16th. HC Wainwright restated a buy rating and issued a $3.50 price objective on shares of Histogenics in a research note on Thursday, November 2nd. Finally, Canaccord Genuity restated a buy rating and issued a $4.00 price objective on shares of Histogenics in a research note on Thursday, December 21st.

Shares of Histogenics (NASDAQ:HSGX) traded up $0.05 on Friday, reaching $2.84. 205,021 shares of the company’s stock were exchanged, compared to its average volume of 223,361. The stock has a market cap of $69.59, a price-to-earnings ratio of -12.91 and a beta of 1.88. Histogenics has a 1-year low of $1.50 and a 1-year high of $3.13.

Histogenics (NASDAQ:HSGX) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. equities research analysts anticipate that Histogenics will post -1.12 earnings per share for the current year.

WARNING: “Histogenics (HSGX) Upgraded at ValuEngine” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2018/02/03/histogenics-hsgx-upgraded-at-valuengine.html.

About Histogenics

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit